Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 2
Therapeutics and Clinical Risk Management
ISSN: 1178-203X
- View all (2328)
- Volume 20, 2024 (20)
- Volume 19, 2023 (91)
- Volume 18, 2022 (104)
- Volume 17, 2021 (134)
- Volume 16, 2020 (134)
- Volume 15, 2019 (154)
- Volume 14, 2018 (271)
- Volume 13, 2017 (188)
- Volume 12, 2016 (217)
- Volume 11, 2015 (210)
- Volume 10, 2014 (113)
- Volume 9, 2013 (57)
- Volume 8, 2012 (47)
- Volume 7, 2011 (59)
- Volume 6, 2010 (66)
- Volume 5, 2009 (102)
- Volume 4, 2008 (148)
- Volume 3, 2007 (126)
- Volume 2, 2006 (47)
- Volume 1, 2005 (40)
Archive: Volume 3, 2007
A smarter way to manage asthma with a combination of a long-acting β2-agonist and inhaled corticosteroid
Olof Selroos
Therapeutics and Clinical Risk Management 2007, 3:349-359
Published Date: 15 May 2007
Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST)
Christophe Le Tourneau, Eric Raymond, Sandrine Faivre
Therapeutics and Clinical Risk Management 2007, 3:341-348
Published Date: 15 May 2007
An overview of the clinical use of ondansetron in preschool age children
Ira Todd Cohen
Therapeutics and Clinical Risk Management 2007, 3:333-339
Published Date: 15 May 2007
Montelukast in the management of allergic rhinitis
Jaime A Lagos, Gailen D Marshall
Therapeutics and Clinical Risk Management 2007, 3:327-332
Published Date: 15 May 2007
Diagnosis and treatment of chronic rhinosinusitis: focus on intranasal Amphotericin B
Eugene B Kern, David Sherris, Angelos M Stergiou, Laura M Katz, Lisa C Rosenblatt, Jens Ponikau
Therapeutics and Clinical Risk Management 2007, 3:319-325
Published Date: 15 May 2007
Skin and skin structure infections: treatment with newer generation fluoroquinolones
Philip Giordano, Kurt Weber, Gail Gesin, Jason Kubert
Therapeutics and Clinical Risk Management 2007, 3:309-317
Published Date: 15 May 2007
Infliximab in the treatment of Crohn’s disease
Gilberto Poggioli, Silvio Laureti, Massimo Campieri, Filippo Pierangeli, Paolo Gionchetti, et al
Therapeutics and Clinical Risk Management 2007, 3:301-308
Published Date: 15 May 2007
Exjade® (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion
Maria Domenica Cappellini
Therapeutics and Clinical Risk Management 2007, 3:291-299
Published Date: 15 May 2007
Dapoxetine, a novel selective serotonin transport inhibitor for the treatment of premature ejaculation
Muammer Kendirci, Emad Salem, Wayne JG Hellstrom
Therapeutics and Clinical Risk Management 2007, 3:277-289
Published Date: 15 May 2007
Darbepoetin alpha in the treatment of cancer chemotherapy-induced anemia
Alberto Grossi, Francesca Balestri, Simone Santini
Therapeutics and Clinical Risk Management 2007, 3:269-275
Published Date: 15 May 2007
Natalizumab: A new treatment for relapsing remitting multiple sclerosis
Michael Hutchinson
Therapeutics and Clinical Risk Management 2007, 3:259-268
Published Date: 15 May 2007
The safety of etanercept for the treatment of plaque psoriasis
Kim A Papp
Therapeutics and Clinical Risk Management 2007, 3:245-258
Published Date: 15 May 2007
Long-term management of gastroesophageal reflux disease with pantoprazole
Theo Scholten
Therapeutics and Clinical Risk Management 2007, 3:231-243
Published Date: 15 May 2007
Incidence of spontaneous notifications of adverse reactions with aceclofenac, meloxicam, and rofecoxib during the first year after marketing in the United Kingdom
Anna Raber, Joan Heras, Joan Costa, Josep Fortea, Albert Cobos
Therapeutics and Clinical Risk Management 2007, 3:225-230
Published Date: 15 May 2007
Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors
Jean-Pierre Armand, Vincent Ribrag, Jean-Luc Harrousseau, Lauren Abrey
Therapeutics and Clinical Risk Management 2007, 3:213-224
Published Date: 15 May 2007
Editorial || FREE PAPER ||
Garry M Walsh
Therapeutics and Clinical Risk Management 2007, 3:211-212
Published Date: 15 May 2007